Charles River Partners with Gazi University on Gene Therapy Manufacturing
Thursday, January 22, 2026
Charles River Laboratories International has entered into a manufacturing collaboration with the Faculty of Medicine at Gazi University to support the development of a gene therapy programme focused on a rare genetic disorder.
The partnership will provide plasmid DNA for adeno-associated virus (AAV) production and in vitro efficacy studies.
The collaboration centres on research into hyperphosphatemic tumoral calcinosis (HTC), a rare inherited condition characterised by elevated phosphate levels in the blood and painful calcium phosphate deposits in soft tissues, particularly around major joints. These deposits can cause inflammation, pain, and restricted movement. Researchers at Gazi University have identified defects in the GALNT3 gene as a key cause of the disorder.
As part of the agreement, Charles River will supply pre-manufactured, research-grade AAV plasmids to support early-stage gene therapy development. These plasmids are produced using animal component-free processes and are designed to be ready for immediate use. The approach is intended to help academic researchers advance programmes more efficiently while managing development timelines and costs.
The partnership brings together academic expertise in rare disease genetics with industrial capabilities in cell and gene therapy manufacturing. It is expected to support the translation of laboratory research into potential therapeutic solutions for patients with limited treatment options.
The company provides integrated solutions across the development lifecycle, from preclinical research through to commercial-scale production of plasmid DNA, viral vectors, and cell-based therapies.
Charles River continues to expand its cell and gene therapy CDMO offering, which spans discovery support, safety assessment, biologics testing, and manufacturing services.
Source: criver.com
